| AgendaAgenda at a Glance| February 4, 2010 : Thursday | | 7:30 | Registration and Morning Coffee | | 8:15 | KEYNOTE PRESENTATION: A Passion for DNA: Genes, Genomes, and Society Dr. James Watson, Co-Discoverer, DNA DOUBLE HELIX | | 9:30 | Chairperson’s Welcome & Solutions Summit Meet & Greet - Jeffrey S. Humphrey, M.D., Vice President, Oncology Medical Strategy, U.S. Pharmaceuticals Medical Affairs, BRISTOL-MYERS SQUIBB
| | 10:00 | 30-Minute Networking Break in Exhibit Hall | | 10:30 | Strategic Use of Biomarkers in Oncology Drug Development - John Brandt, MD, Oncology Biomarker Sciences Group, ELI LILLY
| | 11:15 |
Gene Expression Profiling as a Target Engagement and Safety Biomarker - Samuel C. Blackman, M.D., Ph.D., Associate Director, Experimental Medicine, MERCK
| | 12:00 | Moderated Q&A: TARGET Solutions Summit Discussion - Moderator: Jeffrey S. Humphrey, M.D., Vice President, Oncology Medical Strategy, U.S. Pharmaceuticals Medical Affairs, BRISTOL-MYERS SQUIBB
- Panelists: John Brandt, MD, Oncology Biomarker Sciences Group, ELI LILLY
- Samuel C. Blackman, M.D., Ph.D., Associate Director, Experimental Medicine, MERCK
| | 12:15 | Networking Luncheon
Expert Exchange Luncheon, Network with the Faculty and Scientific Advisors | | 1:30 | Translational Sciences in Oncology a Risk Mitigation Strategy - Theresa LaVallee, PhD, Director, Translational Sciences Oncology, MEDIMMUNE
| | 2:15 | Integrated Approaches For Developing Clinical Biomarker Strategies - Ann Kapoun, PhD, Director, Translational Medicine, ONCOMED PHARMACEUTICALS
| | 3:00 | Panel Discussion
TARGET Solutions Summit Discussion - Moderator: Jeffrey S. Humphrey, M.D., Vice President, Oncology Medical Strategy, U.S. Pharmaceuticals Medical Affairs, BRISTOL-MYERS SQUIBB
- Panelists: Stephanie H. Astrow, PhD, MBA, QUEST DIAGNOSTICS
- Theresa LaVallee, PhD, Director, Translational Sciences Oncology, MEDIMMUNE
- Ann Kapoun, PhD, Director, Translational Medicine, ONCOMED PHARMACEUTICALS
| | 3:30 | 45-Minute Networking Break in Exhibit Hall | | 4:15 | Challenges In Sample Management When Implementing Longitudinal Biomarker Testing - Crystal Sung, PhD, D(ABMLI), Scientific Director, GENZYME CORPORATION
| | 4:45 | Round Table Discussions | | 5:15 | Quest Diagnostics' Wine Tasting Reception |
| February 5, 2010 : Friday | | 7:30 | Morning Coffee | | 8:15 | Chairperson’s Recap of Day One - Jeffrey S. Humphrey, M.D., Vice President, Oncology Medical Strategy, U.S. Pharmaceuticals Medical Affairs, BRISTOL-MYERS SQUIBB
| | 8:30 |
Challenges and Lessons Learned in Developing Therapeutic Combinations - Jon Wigginton, MD, Group Medical Director, Discovery Medicine-Clinical Oncology, BRISTOL-MYERS SQUIBB
| | 9:15 | Best Practices for Growing Incorporation of Companion Diagnostics in Oncology Studies - Lin Wu, Ph.D., Director, Genomics & Oncology, ROCHE MOLECULAR SYSTEMS
| | 9:45 | Implementation of Imaging Metrics to Monitor Oncology Studies -
- Natasha F. Homji, MS, Study Manager II, Oncology Imaging, NOVARTIS PHARMACEUTICALS
| | 10:15 | 45-Minute Networking Break in Exhibit Hall | | 11:00 | Practical Considerations in Successful Implementation of Exploratory Imaging in Early Phase Trials - Haren Rupani, M.D, Global Head, Oncology Clinical Imaging, NOVARTIS PHARMACEUTICALS
| | 11:30 | - Panel Discussion
Day Two Deep Dive Rehash
| | 12:00 | Conference Concludes |
|
